Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: The clopidogrel Medco outcomes study

Pharmacotherapy

Volumn 30, Issue 8, 2010, Pages 787-796

  Kreutz, Rolf P ^a,b   Stanek, Eric J ^c   Aubert, Ronald ^c   Yao, Jianying ^c   Breall, Jeffrey A ^b   Desta, Zeruesenay ^a   Skaar, Todd C ^a   Teagarden, J Russell ^c   Frueh, Felix W ^c   Epstein, Robert S ^c   Flockhart, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Medco Health Solutions   (United States)

Author keywords

Catheterization; Clopidogrel; Myocardial infarction; PPI; Proton pump inhibitor; Stents; Stroke

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DRUG ELUTING STENT; DRUG METABOLISM; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; RECURRENCE RISK; RETROSPECTIVE STUDY; UPPER GASTROINTESTINAL BLEEDING;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77955452982     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.8.787     Document Type: Article

References (25)

1. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84:236-42.
2. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
3. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
4. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75.
5. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58.
6. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004;5:181-202.
7. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7.
8. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. Circulation 2008;118:1894-909.
9. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol 2008;51:256-60.
10. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84.
11. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5.
12. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44.
13. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18.
14. Pezalla E, Day D, Pulliadath I. Initial assessment of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:1038-9.
15. Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 2010;125:e51-4.
16. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97.
17. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract]. Circulation 2008;118(suppl 2):S815.
18. Society for Cardiovascular Angiography and Interventions. SCAI statement on "a national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study." Available from http://www.scai.org/drlt1.aspx?PAGE-ID=5870. Accessed June 9, 2009.
19. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16.
20. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-9.
21. U.S. Food and Drug Administration. FDA statement. Early communication about an ongoing safety review: omeprazole (Prilosec), esomeprazole (Nexium). August 9, 2007. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm072497.htm. Accessed June 14, 2009.
22. U.S. Food and Drug Administration. FDA statement. Update of safety review, follow-up to the August 9, 2007, communication about the ongoing safety review of omeprazole and esomeprazole. Available from http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143258.htm. Accessed June 14, 2009.
23. Cogentus Pharmaceuticals. Clopidogrel and the optimization of gastrointestinal events (COGENT-1). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/show/NCT00557921. Accessed January 29, 2009.
24. Bhatt DL, Cryer B, Contant CF, et al. The COGENT trial. Presented at the transcatheter cardiovascular therapeutics (TCT 2009) 21st annual scientific symposium, San Francisco, CA, September 21-26, 2009.
25. Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: U.S. FDA recommendations. Pharmacogenomics 2009;10:1799-817.